B. Wallberg

Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial

J. Bergh, N. Wilking, C. Bolund, 2009, Climacteric : the journal of the International Menopause Society.

Tamoxifen and megestrol acetate for postmenopausal breast cancer

N. Wilking, T. Fornander, L. Rutqvist, 2004, Medical oncology.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Michael Gnant, Jonas Bergh, Richard Greil, 2016, JAMA.

The Meaning of Breast Cancer

L. Degner, N. Wilking, C. Bolund, 2003, Acta oncologica.

Health-related quality of life during hormone therapy after breast cancer: a randomized trial

Y. Brandberg, N. Wilking, K. Carlström, 2011, Climacteric : the journal of the International Menopause Society.

Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients.

L. Degner, N. Wilking, C. Bolund, 2000, Acta oncologica.

Breast cancer survivors : Information needs, attitudes towards illness and quality of life

B. Wallberg, 2010 .

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival

M. Fernö, C. Perou, J. Bergh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

R. Greil, J. Bergh, P. Malmström, 2016, JAMA.

A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones.

B. Johansson, A. Nordgren, D. Grandér, 1996, Leukemia.